Biotech Values

[DewDiligence]

Bayer—I don't have the numbers at hand, but most patients enrolled in CORRECT were probably third- or fourth-line patients.

Isn’t the relevant question how many lines of prior treatment patients had to have failed to enroll? I thought the requirement in this instance was only one prior treatment; if so, this is technically a second-line study even if most of the patients had failed more than one prior treatment.